STING1 and neoplasm: In another example, STING agonists were combined with a PD-L1 inhibitor and an OX40 agonist, resulting in not only effectively activation of innate immunity to support T cell priming, but also overcoming the antigen-enforced immune tolerance for tumor regression 50.